Veyonda Aids Radiation Therapy in Reaching Distant Lesions in Late-stage Cancer Trial

Veyonda Aids Radiation Therapy in Reaching Distant Lesions in Late-stage Cancer Trial
Veyonda (idronoxil) given in combination with low-dose radiation therapy was able to shrink metastatic lesions well outside the radiation field in about 27% of men with late-stage metastatic castration-resistant prostate cancer (mCRPC) in the DARRT-1 Phase 1 trial, updated data show. “To our knowledge, this is the first time that anyone has been able to obtain a meaningful abscopal response rate in prostate cancer,” Graham Kelly, PhD, executive chairman and CEO of Noxopharm, which is developing the therapy, said in a press release. Veyonda is an immuno-oncology therapy candidate, meaning that it is designed to act on both cancer cells and the immune system. Considered a radiation sensitizer, it blocks ENOX2, an enzyme involved in cancer cell survival, making cancer cells more vulnerable to the effects of chemotherapy and radiotherapy. Veyonda also activates the
Subscribe or to access all post and page content.